FASN and neoplasm: Co-inhibition of FASN with two mechanistically distinct agents, orlistat and TVB-2640, combined with an anti-PD-L1 antibody robustly suppressed tumor growth in vivo, underscoring the rationale for integrating metabolic inhibition with checkpoint blockade [266].